Accessibility Menu
Rhythm Biosciences logo

Rhythm Biosciences

(ASX) RHY

Current PriceA$0.11
Market CapA$40.05M
Since IPO (2017)-60%
5 Year-89%
1 Year+77%
1 Month-15%

Rhythm Biosciences Financials at a Glance

Market Cap

A$40.05M

Revenue (TTM)

A$5.66M

Net Income (TTM)

-A$8.85M

EPS (TTM)

-A$0.02

P/E Ratio

-4.93

Dividend

A$0.00

Beta (Volatility)

-0.08 (Low)

Price

A$0.11

Volume

325,000

Open

A$0.11

Previous Close

A$0.11

Daily Range

A$0.11 - A$0.12

52-Week Range

A$0.05 - A$0.28

Estimated Earnings Date

Aug 27, 2026

RHY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Rhythm Biosciences

Industry

Healthcare Providers and Services

CEO

David George Atkins, PhD, MBA

Headquarters

Parkville, VIC 3010, AU

RHY Financials

Key Financial Metrics (TTM)

Gross Margin

-64%

Operating Margin

-112%

Net Income Margin

-94%

Return on Equity

-190%

Return on Capital

-4%

Return on Assets

-2%

Earnings Yield

-20.28%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$40.05M

Shares Outstanding

364.06M

Volume

325.00K

Avg. Volume

540.49K

Financials (TTM)

Gross Profit

A$2.97M

Operating Income

-A$3.53M

EBITDA

-A$3.53M

Operating Cash Flow

-A$2.92M

Capital Expenditure

-A$23.21K

Free Cash Flow

-A$2.94M

Cash & ST Invst.

A$1.48M

Total Debt

A$1.11M

Rhythm Biosciences Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

A$46.25K

-97.3%

Gross Profit

-A$2.14M

+16.7%

Gross Margin

-46.24%

N/A

Market Cap

A$40.05M

N/A

Market Cap/Employee

A$1.74M

N/A

Employees

23

N/A

Net Income

-A$2.26M

+44.8%

EBITDA

-A$3.69M

+34.9%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

A$1.73M

+36.8%

Total Debt

A$262.44K

+574.0%

Accounts Receivable

A$61.39K

-19.8%

Inventory

A$73.29K

+1687.7%

Long Term Debt

A$0.00

N/A

Short Term Debt

A$262.44K

+237.0%

Return on Assets

-2.15%

N/A

Return on Invested Capital

-3.70%

N/A

Free Cash Flow

-A$2.22M

+29.0%

Operating Cash Flow

-A$2.22M

+27.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
IIQ.AXINOVIQ Ltd
A$0.32+0.00%
HMD.AXHeraMED Limited
A$0.04+2.70%
BDX.AXBCAL Diagnostics Limited
A$0.07+2.94%
NOX.AXNoxopharm Limited
A$0.08-3.75%

Trending Stocks

Symbol / CompanyPricePrice Chg
AALAmerican Airlines Group
$14.98+0.02%
NOKNokia
$14.80+0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.59+0.04%
TQQQProShares Trust - ProShares UltraPro Qqq
$77.52+0.02%

Questions About RHY

What is the current price of Rhythm Biosciences?

Rhythm Biosciences is trading at A$0.11 per share.

What is the 52-week range for Rhythm Biosciences?

Over the past 52 weeks, Rhythm Biosciences has traded between A$0.05 and A$0.28.

How much debt does Rhythm Biosciences have?

As of the most recent reporting period, Rhythm Biosciences reported total debt of A$1.11M.

How much cash does Rhythm Biosciences have on hand?

Rhythm Biosciences reported A$1.40M in cash and cash equivalents in its most recent financial results.

What is Rhythm Biosciences’s dividend yield?

Rhythm Biosciences does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.